Basic Information | Post buying leads | Suppliers |
Name |
Antimony potassium tartrate |
EINECS | N/A |
CAS No. | 16039-64-8 | Density | N/A |
PSA | 241.44000 | LogP | -9.58400 |
Solubility | N/A | Melting Point |
N/A |
Formula | C4H4KO7Sb.(1/2)H2O | Boiling Point | 399.3oC at 760 mmHg |
Molecular Weight | 457.00000 | Flash Point | 209.4oC |
Transport Information | N/A | Appearance | N/A |
Safety | Risk Codes |
Xn:; | |
Molecular Structure | Hazard Symbols | R20/22;R51/53:; | |
Synonyms |
potassium,antimony(3+),2,3-dihydroxybutanedioate;Potassium Antimony Tartrate; |
IUPAC Name: Antimony potassium tartrate
The MF of Antimony potassium tartrate (16039-64-8) is C4H4KO7Sb.(1/2)H2O.
The MW of Antimony potassium tartrate (16039-64-8) is 333.93.
Synonyms of Antimony potassium tartrate (16039-64-8): Pot antimony(iii)oxide tartrate hemi-hydrate ; Potassium antimony 2,3-hydroxy-2,3-butandioate (R-R*,R*) (on converstion to antimony) ; Bi[(+)-tartrato]diantimonate (!!) dipotassium trihydrate
Stability: Stable. Incompatible with strong oxidizing agents, alkalies, acids, heavy metal salts.Efflorescent
Appearance: white powder
Melting Point: 332 - 335 °C
Antimony potassium tartrate (16039-64-8) is used in organic synthesis, drug manufacturing.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
guinea pig | LD50 | intraperitoneal | 15mg/kg (15mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
guinea pig | LDLo | intramuscular | 55mg/kg (55mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
human | LDLo | oral | 2mg/kg (2mg/kg) | Pesticide Chemicals Official Compendium, Association of the American Pesticide Control Officials, Inc., 1966. Vol. -, Pg. 1097, 1966. | |
human | TDLo | intravenous | 1392ug/kg (1.392mg/kg) | SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Lancet. Vol. 210, Pg. 227, 1926. |
man | LD50 | intravenous | 249mg/kg/9D-I (249mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" GASTROINTESTINAL: NAUSEA OR VOMITING | Journal of Tropical Medicine and Hygiene. Vol. 21, Pg. 38, 1918. |
man | LDLo | intravenous | 12mg/kg/1W-I (12mg/kg) | LIVER: OTHER CHANGES KIDNEY, URETER, AND BLADDER: OTHER CHANGES | Lancet. Vol. 210, Pg. 227, 1926. |
mouse | LD50 | intraperitoneal | 33mg/kg (33mg/kg) | Bulletin of the World Health Organization. Vol. 53, Pg. 379, 1976. | |
mouse | LD50 | intravenous | 45mg/kg (45mg/kg) | Fortschritte der Arzneimittelforschung. Progress in Drug Research. Vol. 17, Pg. 108, 1973. | |
mouse | LD50 | subcutaneous | 55mg/kg (55mg/kg) | BEHAVIORAL: MUSCLE WEAKNESS LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Proceedings of the Society for Experimental Biology and Medicine. Vol. 129, Pg. 284, 1968. |
mouse | LDLo | oral | 600mg/kg (600mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
rabbit | LD50 | intravenous | 12mg/kg (12mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 89, Pg. 196, 1947. | |
rabbit | LD50 | oral | 115mg/kg (115mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
rat | LD50 | intraperitoneal | 11mg/kg (11mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. | |
rat | LD50 | oral | 115mg/kg (115mg/kg) | Agricultural Research Service, USDA Information Memorandum. Vol. 20, Pg. 24, 1966. | |
rat | LDLo | intramuscular | 33mg/kg (33mg/kg) | Environmental Quality and Safety, Supplement. Vol. 1, Pg. 1, 1975. |
Safety glasses, good ventilation, gloves